Pancreatic cancer drug daraxonrasib from Revolution Medicines succeeds in trial

Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus…